AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure We continue to believe AbbVie needs to expand its late-stage pipeline.

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by investors including Pfizer Ventures, Novartis Venture Fund, Eli Lilly and ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

AbbVie’s focus on building a strong portfolio, particularly in immunology and neurology, further supports the Buy rating. The company’s plans to enhance its offering with promising trial ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie forecasts 7% growth in 2025 and 10-11% in 2026-2027 for its immunology segment. Goldman Sachs raises AbbVie’s price target to $208, citing Skyrizi and Rinvoq as key growth drivers.

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

AbbVie has announced that it will be expanding its immunology pipeline by acquiring Nimble Therapeutics for $200m. The deal gives AbbVie access to Nimble’s lead asset, an investigational oral peptide ...